[email protected] | |
3275638434 | |
Paper Publishing WeChat |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Tamoxifen Treatment
and Risk of Endometrial Cancer: An Overview
Fadila Kouhen, Fadoua Rais, Naoual Benhmidou, Mohammed Afif, Sanaa Elmajjaoui, Hanan Elkacemi, Tayeb Kebdani and Noureddine Benjaafar
Full-Text PDF XML 887 Views
DOI:10.17265/2328-7136/2016.01.001
For several decades, tamoxifen has proven effective in reducing recurrence and mortality for early and metastatic breast cancer with positive estrogen receptors, and has been proven to be beneficial in preventing breast cancer in high-risk women. However, tamoxifen has been associated with an increased risk of endometrial cancer by its agonist effects on the endometrium in postmenopausal women. The purpose of this article, through an exhaustive summary of literature, is to provide a better understanding of this relationship and its impact on managed care on patients.
Tamoxifen, endometrial cancer, screening